Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Artigo em Inglês | MEDLINE | ID: mdl-33580923

RESUMO

BACKGROUND: Topical corticosteroids are the standard therapy for the treatment of alopecia areata. Recently, topical latanoprost has been found effective in the treatment of eyelash alopecia areata. OBJECTIVES: The objective of this study was to compare the efficacy of topical latanoprost ophthalmic solution (group 1) with that of topical betamethasone diproprionate lotion (group 2) in the treatment of localized alopecia areata. METHODS: This was a single-centre, randomized, two-armed, parallel-group efficacy trial. Fifty consecutive patients with localized alopecia areata were randomized in a 1:1 ratio to receive either topical latanoprost 0.005% ophthalmic solution or topical betamethasone diproprionate 0.05% lotion. Of these 50 patients, 44 patients (21 in group 1 and 23 in group 2) completed the treatment protocol. RESULTS: The percentage reduction in area involved with alopecia areata at 16 weeks (primary outcome) was lower in latanoprost vs. betamethasone group (median [interquartile range], 11.1 [0-99.1] vs. 100% [13.6-100], P = 0.02). Significantly lesser patients in the latanoprost group had a complete response to treatment as compared to the betamethasone group (6 [24%] vs. 14 [56%], P = 0.02). The median (interquartile range) hair regrowth score was significantly lower in the latanoprost vs. the betamethasone group (1 [0-4.5] vs. 5 [1-5], P = 0.02). Subjects in the betamethasone group showed a more rapid reduction in the involved area. LIMITATIONS: Short duration of treatment and follow-up were limitations of this study. CONCLUSION: Our results suggest that topical latanoprost 0.005% ophthalmic solution is less effective but safer than topical betamethasone dipropionate 0.05% lotion in the treatment of localized alopecia areata (clinicaltrials.gov: NCT02350023).


Assuntos
Alopecia em Áreas/tratamento farmacológico , Betametasona/análogos & derivados , Fármacos Dermatológicos/uso terapêutico , Latanoprosta/uso terapêutico , Administração Tópica , Adolescente , Adulto , Betametasona/uso terapêutico , Feminino , Humanos , Masculino , Adulto Jovem
2.
J Biomater Sci Polym Ed ; 31(1): 1-19, 2020 01.
Artigo em Inglês | MEDLINE | ID: mdl-31526302

RESUMO

This study investigated the potential of delivering an anti-glaucoma drug using commercial silicone hydrogel (SiHy) contact lenses. The moderately hydrophobic drug latanoprost was rapidly loaded in 4 min by swelling contact lenses in a solution of the drug in n-propanol. A fraction of the drug was radiolabeled, thus allowing measurement of the uptake and subsequent release of drug into artificial tear fluid. Three questions were addressed: (1) how much drug can be loaded into each type of lens, (2) how fast is drug release, and (3) how are these values related to the contact lens chemistry. The results showed that much more latanoprost could be loaded into SiHy lenses than a conventional contact lens of poly(hydroxyethyl methacrylate). The drug uptake correlated with the amount of swelling in n-propanol, with Galyfilcon lenses having the greatest swelling and highest drug uptake. The drug release from the SiHy lenses occurred over days, whereas the conventional lens released nearly all drug in a burst over a few hours. To examine correlations between lens chemistry, drug chemistry and uptake, and solvent chemistry, the Hansen solubility parameters were calculated using estimates of contact lens chemistry. These results showed that drug uptake in SiHy lenses correlated with favorable solubility parameter interactions between the n-propanol and the lens material, but did not correlate with interactions between the drug and the lens materials.


Assuntos
Lentes de Contato Hidrofílicas , Latanoprosta/química , Liberação Controlada de Fármacos , Cinética , Solventes/química
3.
Indian J Dermatol Venereol Leprol ; 78(5): 599-604, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22960816

RESUMO

BACKGROUND: There is a need to develop an in vitro skin models which can be used as alternative system for research and testing pharmacological products in place of laboratory animals. Therefore to study the biology and pathophysiology of pigmentation and vitiligo, reliable in vitro skin pigmentation models are required. AIM: In this study, we used primary cultured melanocytes and keratinocytes to prepare the skin co-culture model in control and vitiligo patients. METHODS: The skin grafts were taken from control and patients of vitiligo. In vitro co-culture was prepared after culturing primary melanocytes and keratinocytes. Co- cultures were treated with melanogenic stimulators and inhibitors and after that tyrosinase assay, MTT assay and melanin content assay were performed. RESULTS: Melanocytes and keratinocytes were successfully cultured from control and vitiligo patients and after that co-culture models were prepared. After treatment of co-culture model with melanogenic stimulator we found that tyrosinase activity, cell proliferation and melanin content increased whereas after treatment with melanogenic inhibitor, tyrosinase activity, cell proliferation and melanin content decreased. We also found some differences in the control co-culture model and vitiligo co-culture model. CONCLUSION: We successfully constructed in vitro co-culture pigmentation model for control and vitiligo patients using primary cultured melanocytes and keratinocytes. The use of primary melanocytes and keratinocytes is more appropriate over the use of transformed cells. The only limitation of these models is that these can be used for screening small numbers of compounds.


Assuntos
Técnicas de Cocultura , Queratinócitos/citologia , Melanócitos/citologia , Modelos Biológicos , Vitiligo/fisiopatologia , Análise de Variância , Proliferação de Células/efeitos dos fármacos , Humanos , Hidroquinonas/farmacologia , Queratinócitos/efeitos dos fármacos , Queratinócitos/metabolismo , Latanoprosta , Melaninas/agonistas , Melaninas/antagonistas & inibidores , Melaninas/metabolismo , Melanócitos/efeitos dos fármacos , Melanócitos/metabolismo , Monofenol Mono-Oxigenase/efeitos dos fármacos , Monofenol Mono-Oxigenase/metabolismo , Pigmentação/fisiologia , Prostaglandinas F Sintéticas/farmacologia , Pironas/farmacologia , Fator de Células-Tronco/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA